The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial
A first-in-class heart failure drug showed excellent safety in 294 patients, with hints of benefit in those with more severe disease deserving further study.
The HF-REVERT phase 2 trial evaluated CDR132L — the first miR-132 inhibitor — in 294 post-MI patients with reduced ejection fraction. Despite excellent tolerability (no hepatic, renal, hematologic, or cardiac toxicity), the drug missed its primary cardiac remodeling endpoint; however, exploratory subgroup analyses hint at potential benefit in patients with more severe baseline remodeling, informing the design of further trials including in chronic heart failure.
What the study was
- Study design
- Multinational randomized double-blind placebo-controlled phase 2 trial (HF-REVERT)
- Population
- Adults with recent MI (3-14 days) and LV systolic dysfunction (reduced LVEF)
- Sample size
- 294
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Nature Medicine
Why it surfaced
NOVEL_TREATMENT flag triggers HIGH despite score 6. First-in-class miR-132 inhibitor tested in a Phase 2 multinational RCT in Nat Med (n=294). PRIMARY ENDPOINT MISSED — this is a negative trial. However, the novel mechanism (miRNA-based cardiac remodeling inhibition), rigorous trial design, high-profile journal, and exploratory signals in advanced remodeling subgroup make it a critical field-informing result. Cardiology and pharma pipelines will need to adjust on this basis.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.